SAN DIEGO--(BUSINESS WIRE)--Inovio Biomedical Corporation (AMEX:INO), which is focused on the development of DNA vaccines for cancers and infectious diseases, announced today it is focusing its research and development efforts on its electroporation-mediated DNA delivery technology and DNA vaccines with the objective of further building potential downstream value to existing and prospective partners. Overall, management has concluded that the potential return on capital invested in Inovio’s DNA delivery technology is significantly greater than the potential return on its Selective Electrochemical Tumor Ablation (SECTA) program. Therefore, Inovio will focus its research and development efforts on the DNA vaccine market while pursuing avenues for commercialization of the SECTA therapy. The company’s strategy is to:
